Factor Viii, Recombinant Human With Fc Fusion
Hemophilia A
Zhengzhou Gensciences IncPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 73/ 100
Competitive context
47 Active assets in the Hemophilia A cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rurioctocog Alfa Pegol Takeda | Phase 4 | BBB |
bay94-9027 Bayer | Phase 4 | BBB |
Emicizumab Emory University | Phase 4 | BBB |
Fitusiran Sanofi | Phase 4 | BBB |
Xyntha Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Factor Viii, Recombinant Human With Fc Fusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →